Updates are available Correction dated 2019-06-04
Click to view Correction: https://doi.org/10.1038/s41589-019-0315-5
-
Authors
Tsvetkov, Peter https://orcid.org/0000-0002-7577-2342
Detappe, Alexandre https://orcid.org/0000-0001-9364-1621
Cai, Kai
Keys, Heather R. https://orcid.org/0000-0003-1371-2288
Brune, Zarina
Ying, Weiwen
Thiru, Prathapan
Reidy, Mairead
Kugener, Guillaume
Rossen, Jordan
Kocak, Mustafa
Kory, Nora
Tsherniak, Aviad https://orcid.org/0000-0002-3797-1877
Santagata, Sandro https://orcid.org/0000-0002-7528-9668
Whitesell, Luke
Ghobrial, Irene M.
Markley, John L.
Lindquist, Susan
Golub, Todd R. https://orcid.org/0000-0003-0113-2403
- License Information
-
More Information
Article History
Received: 20 November 2018
Accepted: 16 April 2019
First Online: 27 May 2019
Competing interests
: T.R.G. is a consultant in GlaxoSmithKline, Sherlock Biosciences and Foundation medicine; co-founder of Sherlock Biosciences and Foundation medicine. S.S. has consulted for RareCyte Inc. A.T. is a consultant for Tango Therapeutics. W.Y. is employed by Ranok Therapeutics Co. Ltd. and is also the sole proprietor of OnTarget Pharmaceutical Consulting LLC.
